Effect of Gut Microbiota and Its Metabolites on the Efficacy of Immunotherapy in Metastatic Colorectal Cancer
Recruiting · NCT06714903 · Observational (researchers observe without assigning treatment) · Lead sponsor: The First Hospital of Jilin University
View the official record on ClinicalTrials.gov →Interventions studied
treatment option-fruquintinib alonetreatment option-sintilimab plus fruquintinib
What this trial is about
The purpose of this observational study is to understand the effect of gut microbiota on the efficacy of immunotherapy in patients with metastatic colorectal cancer and to explore the specific mechanisms of this process. In this way, it provides new ideas for the clinical treatment of colorectal cancer.
Who can take part
Age range
35 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Clinical and pathological diagnosis of metastatic colorectal cancer
- 35-75 years old (both ends inclusive)
- complete clinical information
- signed informed consent
Exclusion criteria
- combined with severe respiratory and circulatory diseases
- combined with other malignant tumors
- recent severe active bleeding, uncontrolled active infection or active peptic ulcer
- moderate to severe renal insufficiency
- other circumstances that are judged by the investigator to be unsuitable for participating in this study
Where it is running
1 location listed.
- The First Hospital of Jilin University - Changchun, Jilin, China